Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms.
Grever M, Andritsos L, Anghelina M, Arons E, Banerji V, Barrientos J, Bhat SA, Blachly J, Broccoli A, Call T, Dearden C, Dietrich S, Else M, Epperla N, Fagarasanu A, Falini B, Forconi F, Gozzetti A, Hampel P, Hermel DJ, Iyengar S, Johnston JB, Juliusson G, Kreitman RJ, Lauria F, Lozanski G, Oakes CC, Parikh SA, Park J, Quest G, Rai K, Ravandi F, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Tiacci E, Troussard X, Wörmann B, Zent CS, Zenz T, Zinzani PL. Grever M, et al. Among authors: epperla n. Leukemia. 2024 Jul;38(7):1642-1644. doi: 10.1038/s41375-024-02280-0. Epub 2024 Jun 8. Leukemia. 2024. PMID: 38851853 Free PMC article. No abstract available.
Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.
Epperla N, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani AR, Smith SM, Sureda A, Fenske TS, Kharfan-Dabaja MA, Armand P, Hamadani M. Epperla N, et al. J Hematol Oncol. 2017 Jun 12;10(1):117. doi: 10.1186/s13045-017-0487-y. J Hematol Oncol. 2017. PMID: 28606176 Free PMC article.
Chemotherapy: Response and Survival Data #99.
Epperla N, Weissman DE. Epperla N, et al. J Palliat Med. 2016 Sep;19(9):1011. doi: 10.1089/jpm.2016.0221. Epub 2016 Jun 2. J Palliat Med. 2016. PMID: 27254377 No abstract available.
Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections.
Raj RV, Hari P, Pasquini M, Epperla N, D'Souza A, Fenske T, Shaw BE, Rizzo JD, Drobyski W, Hamadani M. Raj RV, et al. Among authors: epperla n. Bone Marrow Transplant. 2016 Dec;51(12):1602-1604. doi: 10.1038/bmt.2016.216. Epub 2016 Sep 5. Bone Marrow Transplant. 2016. PMID: 27595288 No abstract available.
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies.
Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, Hamadani M. Costa LJ, et al. Among authors: epperla n. Am J Hematol. 2017 Feb;92(2):161-170. doi: 10.1002/ajh.24615. Am J Hematol. 2017. PMID: 27880984 Free PMC article.
Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.
Epperla N, Ahn KW, Armand P, Jaglowski S, Ahmed S, Kenkre VP, Savani B, Jagasia M, Shah NN, Fenske TS, Sureda A, Smith SM, Hamadani M. Epperla N, et al. Biol Blood Marrow Transplant. 2018 Jan;24(1):78-85. doi: 10.1016/j.bbmt.2017.10.011. Epub 2017 Oct 13. Biol Blood Marrow Transplant. 2018. PMID: 29032272 Free PMC article.
160 results